Researchers across the UK have begun recruiting for a large-scale trial of a peer-led workshop designed to encourage early diagnosis of prostate cancer among Black men, a group that faces roughly double the risk of both developing and dying from the disease compared with white men.
The study, known as PROCAN-B+, builds on a smaller pilot that showed promising results. The protocol was published on 19 November 2026 in Frontiers in Public Health.
Prostate cancer is the most commonly diagnosed cancer among men in the UK, accounting for about 28% of new male cancer diagnoses, with roughly 57,898 new cases and around 12,300 deaths each year, according to the study authors. Incidence is projected to rise to about 85,100 new cases annually by 2038–2040.
Black men in England have prostate cancer incidence rates 2.1 times higher than white men, the researchers report, citing national data. Lifetime risk of diagnosis is estimated to be two to three times higher among Black British men, and they are about twice as likely to die from the disease. Despite this, only about a quarter of Black men are aware of their elevated risk, the paper notes.
The intervention at the heart of the trial is a two-hour workshop co-designed with a group of 13 Black men. It includes peer-led discussions about barriers to accessing prostate cancer care, health education delivered by a Black general practitioner, activities to build confidence in communicating with doctors and reception staff, and video testimonials from prostate cancer survivors, women, and religious leaders. The session ends with a social gathering over African and Caribbean food.
The pilot study, evaluated through focus groups with 40 participants and a pre-post survey of 41 participants, found that men found the workshop acceptable, informative and enjoyable. Survey results showed significant increases in prostate cancer knowledge, concern about screening-related risks, and intention to discuss prostate health checks with a doctor. However, the sample was small, and the authors state that more robust effectiveness testing is needed.
The PROCAN-B+ trial is a multi-centre, two-arm, individually randomised, wait-list controlled study. Researchers aim to recruit 330 participants through community networks across three sites: North-East England including Leeds, London, and Scotland. Participants will be randomly assigned to receive the intervention immediately or to a wait-list control group that receives usual care and the workshop after six months. Community members will be trained to deliver the intervention.
The primary outcome is decision self-efficacy — participants' confidence in their ability to engage in informed shared decision-making with a doctor about prostate cancer and PSA testing. Secondary outcomes include knowledge, attitudes and beliefs about prostate cancer risk and PSA testing, intentions to discuss prostate health with a doctor, self-reported discussions and PSA testing, and doctor-verified PSA testing. Survey data will be collected at baseline, immediately after the intervention, and at three- and six-month follow-ups. A qualitative process evaluation using interviews and focus groups will explore acceptability and implementation.
The trial is registered on ClinicalTrials.gov under identifier NCT07620717.
The researchers note that the NHS does not currently recommend routine screening for prostate cancer but encourages anyone worried about their risk to talk to their GP or ask about a PSA test. The study authors argue that culturally tailored interventions may be more effective than generic public health campaigns at addressing the specific barriers Black men face, including lack of awareness of elevated risk, difficulty discussing sensitive health issues, mistrust of healthcare providers, and experiences of institutional racism.
If the intervention proves effective, the authors say it could help reduce prostate cancer inequalities by improving awareness, encouraging help-seeking, and supporting earlier diagnosis for better outcomes.